Omeros upgraded at Cantor on Yartemlea opportunity
Seeking Alpha News (Tue, 22-Sep 1:07 PM ET)
Surging YARTEMLEA Revenues and Bold Debt Reduction Mark Omeros’ Transformative Quarter
Market Chameleon (Thu, 13-Aug 6:32 AM ET)
Omeros Corporation Reports Second Quarter 2026 Financial Results
Business Wire (Wed, 12-Aug 4:02 PM ET)
Omeros Corporation to Announce Second Quarter Financial Results on August 12, 2026
Business Wire (Mon, 10-Aug 8:00 AM ET)
CMS Grants New Technology Add-On Payment (NTAP) Status to YARTEMLEA
Business Wire (Mon, 3-Aug 8:30 AM ET)
PRNewswire (Thu, 30-Jul 10:01 AM ET)
Globe Newswire (Tue, 21-Jul 12:56 PM ET)
Globe Newswire (Wed, 8-Jul 9:34 AM ET)
Omeros Delivers First Profitable Quarter as YARTEMLEA Launch Transforms Financial Trajectory
Market Chameleon (Thu, 14-May 6:17 AM ET)
Omeros to Announce Q1 2026 Financial Results Amid Key Product Developments and Novo Nordisk Deal
Market Chameleon (Tue, 12-May 5:39 AM ET)
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.
Omeros trades on the NASDAQ stock market under the symbol OMER.
As of September 22, 2026, OMER stock price climbed to $20.45 with 1,993,047 million shares trading.
OMER has a beta of 3.08, meaning it tends to be more sensitive to market movements. OMER has a correlation of 0.12 to the broad based SPY ETF.
OMER has a market cap of $1.48 billion. This is considered a Small Cap stock.
Last quarter Omeros reported $29 million in Revenue and $.02 earnings per share. This beat revenue expectation by $16 million and exceeded earnings estimates by $.34.
In the last 3 years, OMER traded as high as $20.58 and as low as $.92.
The top ETF exchange traded funds that OMER belongs to (by Net Assets): VTI, IWM, VXF, XPH, VTWO.
OMER has outperformed the market in the last year with a price return of +389.2% while the SPY ETF gained +17.7%. OMER has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +98.9% and +7.9%, respectively, while the SPY returned +3.8% and +0.7%, respectively.
OMER support price is $17.89 and resistance is $19.09 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that OMER shares will trade within this expected range on the day.